scholarly journals Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery

2016 ◽  
Vol 73 (1) ◽  
Author(s):  
Jae W. Lee ◽  
Chad A. Komar ◽  
Fee Bengsch ◽  
Kathleen Graham ◽  
Gregory L. Beatty
Keyword(s):  
Pancreatic Cancer ◽  
Drug Discovery ◽  
Mouse Models ◽  
Genetically Engineered ◽  
Genetically Engineered Mouse Models ◽  
Oncology Drug

Genetically Engineered Mouse Models in Drug Discovery Research

2009 ◽  
pp. 37-54 ◽  
Author(s):  
Rosalba Sacca ◽  
Sandra J. Engle ◽  
Wenning Qin ◽  
Jeffrey L. Stock ◽  
John D. McNeish
Keyword(s):  
Drug Discovery ◽  
Mouse Models ◽  
Genetically Engineered ◽  
Genetically Engineered Mouse Models ◽  
Discovery Research ◽  
Drug Discovery Research

Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer

Nanoscale ◽  
2019 ◽  
Vol 11 (45) ◽  
pp. 22006-22018 ◽  
Author(s):  
Vijay Sagar Madamsetty ◽  
Krishnendu Pal ◽  
Sandeep Keshavan ◽  
Thomas R. Caulfield ◽  
Shamit Kumar Dutta ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Mouse Models ◽  
Genetically Engineered ◽  
Inhibit Tumor Growth ◽  
Schematic Representation ◽  
Genetically Engineered Mouse Models ◽  
Tumor Growth And Metastasis ◽  
Nano Formulation ◽  
Immune Competent Mouse

Schematic representation demonstrating the fabrication and in vivo evaluation of an immune-modulatory nano-formulation consisting of irinotecan and curcumin in immune-competent mouse models of pancreatic adenocarcinoma.

scholarly journals Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

2013 ◽  
Vol 6 (1) ◽  
pp. 67 ◽  
Author(s):  
Michela Capello ◽  
Paola Cappello ◽  
Federica Linty ◽  
Roberto Chiarle ◽  
Isabella Sperduti ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Mouse Models ◽  
Genetically Engineered ◽  
Early Sign ◽  
Genetically Engineered Mouse Models

scholarly journals Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 71
Author(s):  
Yuriko Saiki ◽  
Can Jiang ◽  
Masaki Ohmuraya ◽  
Toru Furukawa
Keyword(s):  
Pancreatic Cancer ◽  
Mouse Models ◽  
Tumor Biology ◽  
Genetically Engineered ◽  
Lineage Tracing ◽  
Ductal Adenocarcinoma ◽  
Pancreatic Tumors ◽  
Precursor Lesions ◽  
Genetically Engineered Mouse Models ◽  
Molecular Alterations

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy, and the seventh leading cause of cancer-related deaths worldwide. An improved understanding of tumor biology and novel therapeutic discoveries are needed to improve overall survival. Recent multi-gene analysis approaches such as next-generation sequencing have provided useful information on the molecular characterization of pancreatic tumors. Different types of pancreatic cancer and precursor lesions are characterized by specific molecular alterations. Genetically engineered mouse models (GEMMs) of PDAC are useful to understand the roles of altered genes. Most GEMMs are driven by oncogenic Kras, and can recapitulate the histological and molecular hallmarks of human PDAC and comparable precursor lesions. Advanced GEMMs permit the temporally and spatially controlled manipulation of multiple target genes using a dual-recombinase system or CRISPR/Cas9 gene editing. GEMMs that express fluorescent proteins allow cell lineage tracing to follow tumor growth and metastasis to understand the contribution of different cell types in cancer progression. GEMMs are widely used for therapeutic optimization. In this review, we summarize the main molecular alterations found in pancreatic neoplasms, developed GEMMs, and the contribution of GEMMs to the current understanding of PDAC pathobiology. Furthermore, we attempted to modify the categorization of altered driver genes according to the most updated findings.

scholarly journals The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer

2019 ◽  
Vol 8 (9) ◽  
pp. 1369 ◽  
Author(s):  
Weng ◽  
Lin ◽  
Cheng
Keyword(s):  
Pancreatic Cancer ◽  
Mouse Models ◽  
Cancer Biology ◽  
Gene Knockout ◽  
Genetically Engineered ◽  
Ductal Adenocarcinoma ◽  
Neoplastic Progression ◽  
Driver Genes ◽  
Genetically Engineered Mouse Models ◽  
Oncology Research

Pancreatic cancer is often treatment-resistant, with the emerging standard of care, gemcitabine, affording only a few months of incrementally-deteriorating survival. Reflecting on the history of failed clinical trials, genetically engineered mouse models (GEMMs) in oncology research provides the inspiration to discover new treatments for pancreatic cancer that come from better knowledge of pathogenesis mechanisms, not only of the derangements in and consequently acquired capabilities of the cancer cells, but also in the aberrant microenvironment that becomes established to support, sustain, and enhance neoplastic progression. On the other hand, the existing mutational profile of pancreatic cancer guides our understanding of the disease, but leaves many important questions of pancreatic cancer biology unanswered. Over the past decade, a series of transgenic and gene knockout mouse modes have been produced that develop pancreatic cancers with features reflective of metastatic pancreatic ductal adenocarcinoma (PDAC) in humans. Animal models of PDAC are likely to be essential to understanding the genetics and biology of the disease and may provide the foundation for advances in early diagnosis and treatment.

Sign in / Sign up

Export Citation Format

Share Document